ZVRA ZEVRA THERAPEUTICS, INC. Insider Trading

ZVRA CEO McFarlane sells 91,000 shares at $9.38; stock now -26.8% from 52-week high, company unprofitable with -14.0% revenue decline

Neil F. McFarlane, President and CEO, sold 91,000 shares (91.0K shares) of ZEVRA THERAPEUTICS on 2026-02-02 at $9.38, reducing his holdings by 20.0% from 455,350 shares to 364,350 shares. The transaction comes as ZVRA shares trade 26.8% below their 52-week high of $12.79, while the company reported negative net income of $-544,000.00 in its latest quarter and experienced annual revenue decline of -14.0% year-over-year. McFarlane's prior sales at ZVRA in February 2025 saw the stock subsequently rise 3.6%–4.7% over the following 90 days, suggesting his past sales at this ticker did not precede material declines; the current sale occurs against deteriorating fundamentals (ongoing unprofitability and shrinking revenues) and near the lower bound of the stock's recent range.

Director Favorito acquires 3,175 shares of ZVRA at $7.79; holdings rise 441.6%, stock down 43.2% from 52-week high

Director Tamara A. Favorito purchased 3,175 shares on 2025-09-12 at $7.79, substantially increasing her stake from 719 to 3,894 shares (+441.6% relative to pre-transaction holdings). The purchase occurs after significant price deterioration: ZVRA is trading 43.2% below its 52-week high of $12.79, down 23.0% over the prior 30 days and 20.0% over 90 days. The company faces challenging fundamentals, including annual revenue decline of -14.0% and a negative full-year net income despite recent quarterly profitability, alongside a steep P/E of 145.20. The director's material accumulation at a depressed price level and in the context of operational headwinds creates a data point worth monitoring, though the scale and strategic rationale require deeper investigation.

Director Shih Alvin purchases 20.0K shares of ZVRA at $7.89; stock now at $7.23, down 43.5% from 52-week high.

Director Shih Alvin's purchase of 20,000 shares at $7.89 represents his first entry into ZVRA holdings. The stock has declined significantly since the transaction date, trading at $7.23 (down 23.3% over 30 days and 17.9% over 90 days) and 43.5% below its 52-week high of $12.79. The company's fundamentals present a complex picture: it reported net income of $74.7M against quarterly revenue of $25.9M, yet faces negative full-year results with annual revenue declining 14.0% year-over-year and a P/E ratio of 144.60 suggesting distressed valuation metrics. An insider director establishing a new position during a sustained downtrend warrants attention to the disclosed reasoning and broader context, particularly given the company's recent profitability challenges despite headline quarterly earnings.

Director John B Bode purchased 5,000 shares of ZVRA at $9.16 on 2025-08-19, adding to 40,000 prior holdings; stock down 20.9% in 30 days.

Director John B Bode purchased 5,000 shares at $9.16, increasing holdings to 45,000 shares (+12.5% vs. pre-transaction holdings) at a price -27.4% from the 52-week high and -20.9% over the past 30 days. His prior 5 trades at ZVRA show a 4 of 5 well-timed pattern at the 90-day mark, suggesting he historically purchases near local lows at this ticker. However, the company's recent fundamentals are challenged: annual revenue declined 14.0%, the stock trades at a P/E of 185.60, and despite a recent quarterly net income of $74.7M, the company was unprofitable on a full-year basis. The purchase arrives after sharp recent price weakness, which aligns with his historical buying pattern at ZVRA, but elevated valuation metrics and deteriorating annual profitability warrant scrutiny of whether this represents the beginning of recovery or a continuation of structural decline.

Director Watton Corey Michael buys 300 ZVRA shares at $7.84; stock down -22.6% from 52-week high.

Watton Corey Michael, a Director at ZEVRA THERAPEUTICS, purchased 300 shares at $7.84 on 2025-03-28, increasing his holdings by 20.0% to 1,800 shares total. The transaction occurs when the stock is trading at $7.49, down -22.6% from its 52-week high of $9.68 and down -10.2% over the past 90 days. Reviewing his same-ticker trade history at ZVRA, he has executed 4 prior buys with mixed timing: his October 2024 purchase yielded +13.7% in 30 days and +7.8% in 90 days, while his three 2023 purchases posted negative 30- and 90-day returns, with only 2 of 4 prior purchases achieving positive 90-day returns. The company itself reported a net income of $-33.2M in the latest full year, negative annual revenue growth of -14.0%, and operates unprofitably. The modest transaction value of $2.4K represents a relatively small absolute commitment relative to the director's existing position, and the timing relative to fundamental deterioration and recent price weakness offers limited clarity on directional conviction at this price level.

Director Bode John B purchased 10,000 shares of ZVRA at $7.96 on 2025-03-19, expanding holdings 33.3% to 40,000 shares.

Bode John B purchased 10,000 shares at $7.96, a price 0.62% below the current $8.01 level and within the 52-week range of $4.26–$9.68. The transaction represents a 33.3% increase in his personal shareholdings from 30,000 to 40,000 shares. His prior trading history at ZVRA shows strong timing: 4 of 5 prior buys were well-timed at the 90-day mark, with a 2024-07-12 purchase returning +12.7% in 30 days and +35.0% in 90 days. However, fundamentals present a significant headwind—the company reported net income of $-33,225,000.00 for its most recent full fiscal year and is currently unprofitable, with annual revenue declining 14.0% year-over-year. The purchase occurs against a backdrop of operational challenges rather than a recovery signal, warranting attention to whether this reflects conviction in a turnaround strategy or routine portfolio activity.

ZVRA CEO McFarlane sells 91,817 shares in 2 transactions for $727,389.76; retains 191,516 shares post-sale amid -$33.2M net income.

CEO Neil F. McFarlane executed two separate sales totaling 91,817 shares for $727,389.76, reducing his holdings by 32.4% from 283,333 to 191,516 shares. The sales occurred at $7.86 and $8.05 per share on consecutive trading days, with a blended average of $7.92 against the current price of $8.07. The timing of this substantial disposition follows a period of significant revenue growth (+162.6% year-over-year) but amid persistent unprofitability: the company reported a net income of -$33.2M on quarterly revenue of $3.7M. The sale represents material liquidation by the chief executive while the company remains deeply loss-making, warranting investor review of whether operating metrics justify the growth trajectory.

Director Watton Corey Michael bought 500 ZVRA shares at $7.92; stock now $8.46, up 8.7% in 30 days. Prior ZVRA buys mostly underwater.

Director Watton Corey Michael purchased 500 shares at $7.92 on 2024-10-11, increasing his holdings from 1,000 to 1,500 shares (+50.0% growth in position size). The stock has performed well since the transaction date, rising 8.7% over 30 days and 32.8% over 90 days, currently trading at $8.46. However, this positive near-term performance contrasts sharply with the insider's prior trading history at ZVRA: his three previous purchases (2023-06-23, 2023-06-09, and 2023-05-30) delivered negative 30-day and 90-day returns in two of three cases, with only 1 of 3 prior buys achieving positive 90-day results. His cross-ticker track record shows similar challenges, with an average 90-day return of -6.8% and a 33.33% win rate. ZVRA fundamentals present a turnaround narrative: the company generated $4.4M in quarterly revenue with strong 162.6% annual growth, but reported a $-19.9M net loss and remains unprofitable. The director's repeated accumulation despite prior underwater outcomes warrants observation of whether this reflects genuine conviction or mechanical buying in a volatile, pre-profitability biotech.

CFO LaDuane buys 2,000 ZVRA shares at $6.77; prior 4 buys all well-timed at 90d; cluster pattern with 2 other insiders.

Clifton R. LaDuane, CFO & Treasurer, purchased 2,000 shares at $6.77 on 2024-07-17, increasing his position by 12.1% to 18,469 shares. His prior 4 open-market buys at ZVRA achieved a 100% success rate on the 90-day timing metric, with all trades followed by positive subsequent returns. The transaction coincides with a broader cluster pattern: 2 other insiders also bought within the past 14 days. Stock has appreciated 44.8% over 30 days and 46.4% over 90 days since the buy date, and currently trades at $6.59, down 6.9% from its 52-week high of $7.08. The company reported quarterly revenue of $3.4M with net losses of $16.6M, though annual revenue growth reached 162.6% year-over-year. The convergence of consistent insider buy timing at this ticker, recent multi-insider buying cluster, and strong post-buy price performance relative to historical patterns warrants attention to whether this reflects material non-public information or conviction about recovery trajectory in an unprofitable but rapidly growing biotech.

Director Anderson Thomas doubled ZVRA holding to 20,000 shares, buying 10,000 at $6.81 on 2024-07-16 amid +40.6% 30-day rally.

Anderson Thomas (Director) purchased 10,000 shares at $6.81 on 2024-07-16, doubling his stake from 10,000 to 20,000 shares and committing $68.1K to the transaction. The purchase occurred during strong recent price momentum: ZVRA has gained +40.6% over the past 30 days and +41.0% over 90 days, though the stock currently trades at $6.54, -7.6% from its 52-week high of $7.08. Thomas's prior buy at this ticker on 2023-09-06 generated a +3.8% return over the subsequent 90 days, indicating he has previously timed entries at ZVRA advantageously. However, the company remains unprofitable with net income of $-16.6M against quarterly revenue of $3.4M, despite strong annual revenue growth of +162.6%, which underscores the speculative nature of the position and the importance of tracking whether this transaction's timing will replicate the insider's prior success at this ticker.